Showing 1981-1990 of 5909 results for "".
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopiahttps://modernod.com/news/alcon-canada-launches-total30-multifocal-contact-lenses-for-reusable-lens-patients-with-presbyopia/2482093/Alcon announced the launch of TOTAL30 Multifocal in Canada, the first and only monthly water gradient multifocal contact lens. The new TOTAL30 Multifocal lens is designed to help digital device dryness by utilizing a proprietary water gradient technology to deliver nearly
- Mireca Medicines Awarded Nearly $1 Million from the Foundation Fighting Blindness to Develop Treatments for IRDshttps://modernod.com/news/mireca-medicines-awarded-nearly-1-million-from-the-foundation-fighting-blindness-to-develop-treatments-for-inherited-retinal-diseases/2482085/Mireca Medicines announced it has received a $989,000 'Translational Research Acceleration Program Award' from Foundation Fighting Blindness that will permit the company to further advance the preclinical development of its lead product MM238. In a news
- Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/Azura Ophthalmics announced positive topline efficacy and safety results from a phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD). The trial met its prim
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t
- Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Gene Therapy for LCA1https://modernod.com/news/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-gene-therapy-for-lca1/2481966/Atsena Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). RMAT desi
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgeryhttps://modernod.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain followi
- Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver comb